CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01705340
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:37.267830+00:00
Published At: 2013-09-30T00:00:00+00:00
Record Updated At: 2013-09-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Adenocarcinoma of the Gastroesophageal Junction", "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IV Breast Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-09-30"
protocolSection.identificationModule.nctId: "NCT01705340"
protocolSection.identificationModule.officialTitle: "A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.